Mar 5, 2026
There has been a lot of discussion about Category H at recent events, online and on socials. Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damage pharmacy and supplier profitability? Or will it...
Feb 13, 2026
Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters. It’s a lively discussion, looking at pricing trends over the last 12...
Feb 4, 2026
The House of Lords Public Services Committee has published its report concluding its medicines security inquiry. They argued that it is vital that the UK has strong, resilient medicine supply chains and emphasised the need for clear, proactive leadership. The report...
Jan 7, 2026
To start the year off with a bang, we thought we’d compare the generic product prices we get from our Pharmacy and Dispensing Doctor data suppliers with the Drug Tariff for each product. This obviously excludes some products where there is no Drug Tariff...
Oct 16, 2025
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus. The average market price for this medicine normally hovers around the £5 mark but in late 2019 the drug tariff started to come down from over £10.42...
Sep 16, 2025
Leslie Galloway, EMIG Chairman, shared his analysis of VPAG. Here’s Charles’ key takeaways: · The NHS VPAG rebate is £1bn over 3 years and so is a fixed rebate with risk share. · Global Pharma CEOs have asked for lower rebates and a better deal, that...
